Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 5/20 | 0.56 |
| ▸ | RXRB | P28702 | 5/20 | 0.56 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.52 |
| ▸ | RXRG | P48443 | 4/20 | 0.48 |
| ▸ | PPARD | Q03181 | 3/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | SYK | P43405 | 5/20 | 0.46 |
| ▸ | CFD | P00746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4602156 | 0.91 | PTPN11 (0.60) | PTPN11PTPN1PTPN6PPARDPPARA | |
| SCHEMBL4601299 | 0.90 | PTPN11 (0.60) | RXRARXRBPTPN11PTPN1PTPN6 | |
| SCHEMBL3995376 | 0.90 | RXRB (0.58) | RXRARXRBPTPN11PTPN1PTPN6 | |
| SCHEMBL14610577 | 0.89 | RXRA (0.45) | RXRARXRBPTPN11PTPN1PTPN6 | |
| SCHEMBL4601640 | 0.83 | PTPN11 (0.59) | PTPN11PTPN1PTPN6PPARDPPARA | |
| SCHEMBL3991276 | 0.82 | RXRB (0.62) | RXRARXRBRXRGSYKCFD | |
| SCHEMBL4602854 | 0.82 | PTPN11 (0.57) | PTPN11PTPN1PTPN6PPARDPPARA | |
| SCHEMBL4601780 | 0.81 | PTPN11 (0.60) | RXRARXRBPTPN11PTPN1PTPN6 | |
| SCHEMBL4601679 | 0.81 | PTPN11 (0.64) | PTPN11PTPN1PTPN6CFD | |
| SCHEMBL3991789 | 0.81 | PTPN1 (0.58) | RXRARXRBPTPN1PTPN6RXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060573-A1 | Acyltryptophanols | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-15 | — | — | US | claimed |
| EP-1912970-A2 | ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-04-23 | — | — | EP | disclosed |
| US-20070060573-A1 | Acyltryptophanols | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-15 | — | — | US | disclosed |
| WO-2007017289-A2 | ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060573-A1 | Acyltryptophanols | FSHR, NPY1R, NPY2R | RXRA 1256/4885RXRB 1669/4885PTPN11 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.